The game has changed for MedTech approvals. Following a recent FDA alert, data from third-party testing labs is now under intense scrutiny, creating a hidden barrier to market access. This episode of MedTech Global Insights explores the rising threat of unreliable partner data and what it means for your regulatory submissions.

We dive into the silent rejection wave hitting unprepared companies. One diagnostics firm recently had its 510(k) submission derailed, not by a flaw in their device, but by unverifiable biocompatibility data from a contracted lab. This single oversight forced them into a costly and lengthy re-validation process, delaying their launch by nearly a year.

Key Takeaways:

- Why is the FDA suddenly treating third-party lab data with such suspicion?

- What are the critical warning signs that your partner's data might be flagged?

- How can you audit a contract lab's integrity, not just their certifications?

- What specific clauses must be in your Quality Agreements to mitigate this risk?

- Is your existing submission dossier vulnerable to this new level of review?

- How does this partner verification challenge impact EU and other global submissions?

- What steps can you take today to protect your product launch timeline?

To navigate these new regulatory challenges, contact us at [email protected] or visit https://pureglobal.com/. For FREE AI tools and a comprehensive medical device database, visit https://pureglobal.ai/.